On August 10, PHARMARON rose 3.49% in regular trading, trading at HK$28.6/share, with turnover of HK$213 million.

On the news front, the company's board will convene on August 20 to review and approve its first-half interim results. PHARMARON previously guided H1 revenue of RMB 7.47-7.67 billion, representing 16%-19% year-over-year growth, with net profit increasing 4%-10%. Notably, newly signed orders grew over 30%, with small-molecule CDMO orders surging more than 50%.

The broader CXO sector continued to strengthen, with industry leader WuXi AppTec reporting H1 revenue growth of 38.93% and net profit growth of 29.43%, reinforcing the sector's improving fundamentals. On the same day, WuXi AppTec gained 5.46%, WuXi Biologics rose 5.67%, and GenScript Biotech climbed 5.4%, reflecting broad-based sector momentum driven by strong order pipelines and accelerating earnings delivery across the pharmaceutical outsourcing space.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)